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ABSTRACT
Objective: To compare the risk of lupus-like events
(LLEs) and vasculitis-like events (VLEs) in tumour
necrosis factor-α inhibitor (TNFi)-treated patients with
rheumatoid arthritis (RA) to those receiving non-biological
disease-modifying antirheumatic drugs (nbDMARDs).
Methods: Patients were recruited to the British Society
for Rheumatology Biologics Register—RA, a national
prospective cohort study. Two cohorts recruited between
2001 and 2015: (1) patients starting first TNFi
(adalimumab, etanercept, infliximab and certolizumab)
(n=12 937) and (2) biological-naïve comparison cohort
receiving nbDMARDs (n=3673). The risk of an event was
compared between the two cohorts using Cox
proportional-hazard models, adjusted using propensity
scores. Rates of LLE/VLE were compared between TNFi
and nbDMARD patients.
Results: The crude incidence rates for LLEs were: TNFi
10/10 000 patient-years (pyrs) (95% CI 8 to 13) and
nbDMARD 2/10 000 pyrs (95% CI 1 to 6); for VLEs: TNFi
15/10 000 pyrs (95% CI 12 to 19) and nbDMARD 7/
10 000 pyrs (95% CI 4 to 12). The risk of both events was
highest in the first year of TNFi treatment. After adjusting
for differences in baseline characteristics, there was no
difference in risk of LLEs (adjHR 1.86; 95% CI 0.52 to
6.58) or VLEs (adjHR 1.27; 95% CI 0.40 to 4.04) for TNFi
compared to nbDMARD-treated patients. Infliximab
conferred the highest overall risk, followed by etanercept,
although 95% CIs overlapped following adjustment.
Conclusions: In one of the largest biological registers,
the absolute risk of both events is low. The addition of
TNFi to nbDMARD does not alter the risk of either event in
patients with RA selected for TNFi. This is the first study to
assess the risk of these outcomes in a prospective,
observational cohort.
INTRODUCTION
Tumour necrosis factor-α inhibitor (TNFi)
for the treatment of rheumatoid arthritis (RA)
has been associated with asymptomatic
immunological alterations to autoimmune
pathology with systemic manifestations. A
single case of lupus-like event (LLE) was
reported following two infusions of inﬂiximab
in the ﬁrst TNFi randomised controlled trial.1
The number and spectrum of autoimmune
diseases reported to be induced by TNFi
agents have increased in parallel with their
widespread use. The most commonly
described events are LLEs and vasculitis-like
events (VLEs).2
Key messages
What is already known about this subject?
▸ Lupus-like events (LLEs) and vasculitis-like
events (VLEs) have been reported in association
with tumour necrosis factor-α inhibitor (TNFi)
therapy from spontaneous pharmacovigilance;
however, the actual risk from prospective obser-
vational studies has not been studied.
What does this study add?
▸ This study from BSRBR-RA showed that the
absolute risk of both events was low in the TNFi
group (LLE 10/10 000 patient-years; VLE 15/
10 000 patient-years) and after adjusting for
baseline differences, there was no increased risk
of LLE/VLE in TNFi-treated patients compared to
TNFi-naïve patients.
How might this impact on clinical practice?
▸ The results provide reassurance to patients that
such events are rare in TNFi and TNFi-naïve
patients.
▸ High-disease activity was associated with higher
rates, while concomitant treatment, such as
sulfasalazine use, was associated with lower
rates of LLE/VLE, highlighting the importance of
adequate control of RA joint disease to poten-
tially minimise risk of such events.
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Induction of antinuclear antibodies (ANAs) following
TNFis is well recognised, with a small proportion of
patients developing immune-mediated adverse events
(AEs), including LLE and VLEs.3 Seroconversion to
ANA positivity has been associated with secondary non-
response to TNFi treatment,3 4 and to the development
of antidrug antibodies or immunogenicity5 with mono-
clonal antibody TNFi drugs (inﬂiximab/adalimumab).
Immunogenicity has itself also been linked to a diverse
range of VLEs with varying degrees of severity, from
limited cutaneous involvement to life-threatening sys-
temic manifestations.6 7
Most data on LLEs and VLEs are derived from spontan-
eous pharmacovigilance, case reports and retrospective
studies.8 9 While published data suggest a drug-speciﬁc dif-
ference in ANA seroconversion,3 reports to date do not
enable robust comparison between drugs in terms of
actual clinical AEs. Furthermore, it is not known if factors,
such as concomitant non-biological disease-modifying anti-
rheumatic drugs (nbDMARDs), attenuate the risk of these
events, although their use is associated with reduced
immunogenicity in TNFi-treated patients.10
The primary aim of this study was to determine the
incidence of LLE and VLE in patients with RA treated
with TNFi, compared to biological-naïve patients treated
with nbDMARDs. Additional objectives were to: (1)
evaluate drug-speciﬁc risk, (2) determine the risk of
each outcome following exclusion of putative causes and
(3) identify factors associated with each outcome.
PATIENTS AND METHODS
Participants
The British Society for Rheumatology Biologics
Register—RA (BSRBR-RA) is a UK-based national,
observational, prospective cohort study established in
2001, which aims to study the long-term safety of bio-
logical treatment. Patients starting treatment with TNFi
(inﬂiximab, etanercept, adalimumab and certolizumab)
are enrolled for observational follow-up. As per the UK
national guidelines, patients are eligible for TNFi if they
have active disease (disease activity score of 28 joints
(DAS28) >5.1), despite treatment with at least two
nbDMARDs, one of which should be methotrexate.11 A
comparison cohort of biological-naïve patients with RA,
with active disease (deﬁned as a DAS28 score of ≥4.2),
despite current treatment with nbDMARDs, was recruited
in parallel between 2002 and 2009. Ethical approval for
BSRBR-RA was granted in December 2000 by the North
West Multicentre Research Ethics Committee (reference
00/8/53). Written consent was obtained from all partici-
pants recruited.
Baseline assessment
Baseline demographic and clinical information was col-
lected via clinician questionnaires. Consultants were spe-
ciﬁcally asked if the patient had a history of systemic
vasculitis and nailfold vasculitis prior to starting a
biologic. Other comorbidities, such as systemic lupus
erythematosus (SLE), were recorded via a free text box.
Self-reported ethnicity was captured within the baseline
patient questionnaire. Patients were requested to com-
plete a Stanford Health Assessment Questionnaire
(HAQ).12
Follow-up
Follow-up information, including medication changes
and AEs, were captured via three routes: clinician-
completed questionnaires (6-monthly for 3 years then
annually), patient diaries (6-monthly for ﬁrst 3 years
only) and ﬂagging by the Ofﬁce for National Statistics
who notify the register in the event of death or cancer.
All reports of serious events are follow-up with the hos-
pital to request further information. For LLE, this was
via a disease-speciﬁc pro-forma; for VLE, this was via
open correspondence.
Case definition and verification of AEs
We used all relevant MedDRA codes and free text
searches within the AE reported ﬁelds (see online
supplementary table S4) to identify potential cases. All
possible reported events of either LLE or VLE were
reviewed in detail using information provided to the
register. The types of LLE events described in previous
literature from France, USA and Spain have been het-
erogeneous ranging from dsDNA-positive patients with
cutaneous lupus to fewer ‘full blown’ lupus meeting
ACR classiﬁcation criteria.2 8 13 It has been argued that
LLE associated with TNFi therapy is a distinct syndrome
compared to SLE.14 Since classiﬁcation criteria for
drug-induced lupus does not currently exist, the Dubois’
guidelines for drug-induced lupus were used15 to
provide a more sensitive deﬁnition. The full guidelines
are outlined in online supplementary table S1. Brieﬂy,
this includes continuous treatment with a lupus-inducing
drug for ≥1 month, common or multisystem presenting
symptoms consistent with lupus, laboratory proﬁle con-
sistent with lupus and improvement of symptoms follow-
ing drug cessation. Patients were classiﬁed as having an
LLE if clinically identiﬁed as such and ≥2 criteria were
met. Following veriﬁcation (performed by MJ), LLE
cases were additionally classiﬁed according to standard
SLE classiﬁcation criteria (1997 ACR16 and 2012 SLICC
criteria17) for descriptive purposes only. A single set of
classiﬁcation criteria could not be applied due to the
heterogeneous characteristics of vasculitis events,
ranging from cutaneous to multisystem manifestations.
Therefore, such reports were ﬂagged as such by the
reporting physician; veriﬁcation was performed clinically
following additional requests for clinical information
where necessary.
Statistical analysis
Patients with a physician diagnosis of RA, who had at
least one clinician-completed follow-up form by 31 May
2015, were included. The primary outcome was the ﬁrst
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veriﬁed LLE or ﬁrst veriﬁed VLE per participant follow-
ing the start of TNFi drug (or registration for the
nbDMARD cohort). For the LLE analysis, patients with
known SLE overlap recorded at baseline were excluded.
Patients were excluded from the analysis if they had
known systemic vasculitis at baseline. Events were attribu-
ted to TNFi if they occurred when the patient was receiv-
ing TNFi or within 90 days of the ﬁrst missed dose.
Follow-up time was censored at event of interest, death,
drug stop date (plus 90 days) or last physician follow-up,
whichever came ﬁrst. Only time on a ﬁrst TNFi was
included to best attribute any drug-speciﬁc risk. In the
nbDMARD cohort, follow-up time was censored if the
patient switched to a biological drug.
Crude incidence rates were presented as events per
10 000 patient-years (pyrs). Cox proportional-hazard
models were used to compare event rates between TNFi
and nbDMARD cohorts. Cumulative hazards were com-
pared between the different drugs using Nelson-Aalen
plots. A ﬂexible parametric spline model was used to
model time-varying incidence rates in the TNFi cohort.
Adjustment for differences between cohorts was made
using propensity scores using inverse probability of treat-
ment weights (IPTW; see online supplementary
material). Variables were identiﬁed a priori and
included age, gender, disease duration, HAQ score,
baseline DAS28; rheumatoid factor status, recruitment
year, baseline nbDMARD use, baseline oral steroid use
and ethnicity (the latter variable for the LLE analysis
only). Comorbidity was included as a composite variable
generated from the presence of: ischaemic heart disease
(myocardial infarction and/or angina); stroke, hyperten-
sion, chronic lung disease (asthma, bronchitis or emphy-
sema), renal disease, liver disease, diabetes mellitus or
depression as described previously.18 Ethnicity was strati-
ﬁed as white and non-white for analyses (table 1).
Missing data were replaced using multiple imputation to
avoid the bias induced by a complete case analysis (see
online supplementary table S2).
Two sensitivity analyses were performed. For the LLE
analysis, patients on drugs known to be associated with
drug-induced lupus at baseline (see online
supplementary table S3) and the use of sulfasalazine,
leﬂunomide, minocycline and penicillamine were
excluded.15 19 20 For the VLE analysis, patients who had
a probable secondary vasculitis aetiology (eg, infection
at the time of event), known baseline nailfold vasculitis,
on other medications associated with VLEs at baseline
(see online supplementary table S3) or use of minocy-
cline and penicillamine during the study period were
excluded.21 All analysis was performed using Stata V.13.0
(StataCorp, College Station, Texas, USA).
RESULTS
Baseline characteristics
A total of 3673 nbDMARD and 12 937 TNFi-treated
patients were included (see online supplementary
ﬁgure S1). The TNFi cohort was older, had proportion-
ally more women with higher disease severity (table 1).
Differences between patients treated with inﬂiximab, eta-
nercept and adalimumab were less marked while
patients treated with certolizumab (registered after
2010) had shorter disease duration and less severe
disease at initiation.
Event rates and hazard estimates
There were 59 LLEs (54 TNFi and 5 nbDMARD). The
incidence of LLE was 10/10 000 pyrs (95% CI 8 to 13)
in the TNFi cohort compared to 2/10 000 pyrs (95% CI
1 to 6) in the nbDMARD cohort. After full adjustment,
the risk of LLE in TNFi-treated patients compared to
nbDMARDs was no longer signiﬁcant (adjHR 1.86; 95%
CI 0.52 to 6.58) (table 2). The risk appeared highest for
inﬂiximab (ﬁgure 1). Female gender, non-white ethni-
city, baseline DAS28 score, baseline HAQ score and min-
ocycline use were associated with increased risk of LLE,
while baseline and concomitant sulfasalazine use were
associated with lower rates (table 3). Following exclusion
of patients on drugs known to be associated with
drug-induced lupus, the adjHR was 2.33 (95% CI 0.56 to
9.71) (see online supplementary table S3).
There were 95 cases of VLEs (81 TNFi and 14
nbDMARD) giving an incidence rate for VLE in the
TNFi cohort of 15/10 000 pyrs (95% CI 12 to 19) and
7/10 000 pyrs (95% CI 4 to 12) in the nbDMARD
cohort. Following adjustment using IPTW, there was no
signiﬁcant difference in the risk of VLE for TNFi com-
pared to nbDMARD-exposed patients (adjHR 1.27; 95%
CI 0.40 to 4.04; table 2). Rheumatoid factor-positive
status, disease duration, baseline DAS28 and HAQ scores
were associated with a higher risk while baseline and
concomitant sulfasalazine and concomitant methotrex-
ate were associated with a lower risk (table 3). Exclusion
of secondary causes leading to VLE demonstrated no sig-
niﬁcant differences between groups (adjHR 1.05; 95%
0.32 to 3.45; see online supplementary table S3).
TNFi median time to ﬁrst LLE was 1.2 years for TNFi
patients (IQR 0.6–2.5) and 1.0 year (IQR 0.9–1.4) for
nbDMARD patients. For VLEs, median time to event was
1 year (IQR 0.5–2.5) compared to 1.8 years (IQR 0.9–
3.3) for TNFi and nbDMARD patients, respectively. The
hazard for LLE and VLE in the TNFi-treated cohort was
greatest in the early months of treatment (ﬁgure 2)
then steadily decreased over the course of follow-up.
Characteristics of events
For LLE, 48/54 (89%) patients exposed to anti-TNF had
cutaneous involvement and was the sole manifestation
(plus ANA-positive or consistent skin biopsy) in 30/54
(56%). Of the LLE cases, three patients were known to
be ANA-positive at baseline with no SLE manifestations
prior to treatment. Five patients (4 TNFi and 1
nbDMARD) were reported to have renal involvement
with biopsy results available in three patients (class IV
lupus nephritis, immune complex glomerulopathy on
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Table 1 Baseline characteristics of nbDMARD and TNFi-treated patients
First TNFi drug
nbDMARD
(n=3673)
All TNFi
(n=12 937) p Value*
Etanercept
(n=4516)
Adalimumab
(n=4362)
Infliximab
(n=3363)
Certolizumab
(n=696) p Value†
Demographic features
Age, mean (SD) years 60 (12) 56 (12) <0.001 56 (12) 57 (12) 56 (12) 56 (12) 0.012
Gender, % female 72 76 <0.001 77 76 76 76 0.62
Rheumatoid factor-positive, % 2135 (58) 8199 (63) <0.001 2883 (64) 2688 (62) 2250 (67) 378 (58) <0.001
Ethnicity
White 2952 (80) 10 467 (81) <0.001 3638 (81) 3588 (83) 2795 (83) 446 (64)
Black 24 (0.6) 86 (0.7) 28 (0.6) 34 (0.8) 19 (0.6) 5 (0.7) 0.42
South Asian 32 (0.9) 228 (2) 82 (2) 73 (2) 65 (2) 8 (1)
Chinese 2 (0.1) 31 (0.2) 9 (0.2) 12 (0.3) 9 (0.2) 1 (0.2)
Other 15 (0.4) 117 (0.9) 36 (0.8) 31 (0.7) 41 (1.2) 9 (1)
Not recorded 648 (18) 2002 (16) 723 (16) 624 (14) 428 (13) 227 (32)
Smoking history, n (%)
Current smoker 869 (24) 2762 (21) <0.001 911 (20) 980 (23) 734 (22) 137 (20) <0.001
Former smoker 1452 (40) 4888 (38) 1728 (38) 1660 (38) 1274 (38) 226 (33)
Never smoked 1334 (36) 5159 (40) 1830 (41) 1683 (38) 1338 (40) 308 (44)
Not recorded 18 (0.5) 128 (1) 47 (1) 39 (1) 17 (0.5) 25 (3)
Disease duration, median (IQR) 6 (1–15) 10 (5–18) <0.001 11 (5–19) 10 (5–18) 12 (6–19) 5 (2–12) <0.001
DAS28 score, mean (SD) 5.1 (1.3) 6.5 (1) <0.001 6.5 (1) 6.4 (1) 6.6 (1) 5.9 (1) <0.001
HAQ score, mean (SD) 1.5 (0.8) 2.0 (0.6) <0.001 2.0 (0.6) 1.9 (0.6) 2.1 (0.6) 1.5 (0.8) <0.001
Comorbidity, n (%)
None 1544 (42) 6031 (47) <0.001 2026 (45) 2060 (47) 1582 (47) 363 (52) 0.001
1 comorbidity 1270 (35) 4397 (34) 1522 (34) 1476 (34) 1177 (35) 222 (32)
2 comorbidity 596 (16) 1839 (14) 701 (15) 601 (14) 457 (14) 80 (11)
≥3 comorbidities 263 (7) 670 (5) 267 (6) 225 (5) 147 (4) 31 (5)
Treatment-related factors
Number of prior nbDMARDS,
median (IQR)
2 (1–3) 3 (3–5) <0.001 4 (3–5) 3 (2–4) 4 (3–5) 3 (2–3) <0.001
On methotrexate, n (%) 2449 (67) 7932 (61) <0.001 1921 (43) 2554 (59) 2983 (89) 474 (68) <0.001
On sulfasalazine, n (%) 1245 (34) 2395 (18) <0.001 682 (15) 971 (22) 513 (15) 229 (33) <0.001
On leflunomide, n (%) 495 (13) 1182 (9) <0.001 377 (8) 495 (11) 244 (7) 66 (9) <0.001
On azathioprine, n (%) 93 (2) 309 (2) 0.62 123 (3) 91 (2) 92 (3) 3 (0.4) 0.001
On minocycline, n (%) 1 (0.03) 18 (0.1) 0.08 5 (0.1) 7 (0.2) 6 (0.2) 0 0.63
On hydroxychloroquine, n (%) 639 (17) 1842 (14) <0.001 519 (11) 716 (16) 348 (10) 259 (37) <0.001
Baseline steroid use, n (%) 836 (23) 5348 (41) <0.001 2018 (45) 1617 (37) 1541 (46) 172 (25) <0.001
*p Value represents the significance of differences between the nbDMARD and TNFi cohorts using χ2 tests for categorical outcomes and Wilcoxon rank sum tests for continuous variables.
†p Value represents the significance of differences between the four TNFi drugs using χ2 tests for categorical outcomes and Kruskal-Wallis rank tests for continuous variables. Values <1 are
represented up to one decimal point.
DAS28, 28 joint count Disease Activity Score; HAQ, Health Assessment Questionnaire; nbDMARDs, non-biological disease-modifying antirheumatic drugs; TNFi, tumour necrosis factor-α
inhibitor.
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Table 2 Crude incidence rates and HRs for lupus/vasculitis type events in nbDMARD and TNFi-treated patients (on drug+90 days analysis)
nbDMARD
(n=3673)
All TNFi
(n=12 937)
Etanercept
(n=4516)
Adalimumab
(n=4362)
Infliximab
(n=3363)
Certolizumab
(n=696)
Lupus-like events
Total follow-up time (patient-years) 20 815 53 159 21 595 17 343 13 181 1040
Follow-up per subject, median (IQR) 6.5 (3.4–9.0) 5.1 (2.0–8.9) 6.3 (2.5–10.0) 5.3 (2.2–8.0) 4.2 (1.6–8.4) 1.5 (0.8–2.6)
Number 5 54 20 11 23 0
Crude incidence rate of lupus-like event
per 10 000 person-years (95% CI)
2.4 (1.0 to 5.7) 10.2 (7.8 to 13.2) 9.3 (6.0 to 14.3) 6.3 (3.5 to 11.5) 17.5 (11.6 to 26.3) –
Unadjusted HR (95% CI) Referent 3.93 (1.57 to 9.83)* 3.83 (1.44 to 10.21)* 2.40 (0.83 to 6.92) 6.59 (2.50 to 17.36)* –
Age and gender adjusted (95% CI) Referent 3.72 (1.47 to 9.35)* 3.60 (1.34 to 9.64)* 2.26 (0.78 to 6.53) 6.28 (2.38 to 16.61)* –
Propensity score adjusted HR (95% CI)† Referent 1.86 (0.52 to 6.58) 1.41 (0.41 to 4.90) 1.77 (0.33 to 9.36) 2.65 (0.75 to 9.35) –
n=3640 n=12 745 n=4450 n=4312 n=3292 n=691
Vasculitis-like events
Total follow-up time (patient-years) 20 635 52 428 21 320 17 172 12 903 1033
Follow-up per subject; median (IQR) 6.5 (3.4–9.0) 5.1 (2.0–8.9) 6.3 (2.5–10.0) 5.3 (2.2–8.0) 4.2 (1.6–8.5) 1.5 (0.8–2.6)
Number of vasculitis-like events, n 14 81 37 18 26 0
Crude incidence rate of vasculitis-like
events per 10 000 person-years (95% CI)
6.8 (4.0 to 12.4) 15.5 (12.4 to 19.2) 17.4 (12.6 to 24.0) 10.5 (6.6 to 16.6) 20.2 (13.7 to 29.6) –
Unadjusted HR (95% CI) Referent 2.12 (1.20 to 3.74)* 2.58 (1.39 to 4.77)* 1.38 (0.69 to 2.78) 2.70 (1.41 to 5.18)* –
Age- and gender-adjusted HR (95% CI) Referent 2.31 (1.30 to 4.09)* 2.84 (1.52 to 5.28)* 1.50 (0.74 to 3.03) 2.93 (1.52 to 5.64)* –
Propensity score-adjusted HR (95% CI)‡ Referent 1.27 (0.40 to 4.04) 1.72 (0.53 to 5.57) 0.71 (0.21 to 2.47) 1.55 (0.46 to 5.20) –
*p<0.05.
†Adjusted for age, gender, disease duration, baseline DAS28 score, baseline HAQ score, comorbidities, rheumatoid factor-positive status, year of recruitment, baseline steroid use, baseline
nbDMARD use and ethnicity.
‡Adjusted for age, gender, disease duration, baseline DAS28 score, baseline HAQ score, comorbidities, rheumatoid factor-positive status, year of recruitment, baseline steroid and nbDMARD
use.
DAS28, 28 joint count Disease Activity Score; HAQ, Health Assessment Questionnaire; nbDMARDs, non-biological disease-modifying antirheumatic drugs; TNFi, tumour necrosis factor-α
inhibitor.
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inﬂiximab and adalimumab, respectively; membranous
glomerulonephritis in biological-naïve patient on metho-
trexate). Only 16.7% and 20% of events met ACR 1997
SLE classiﬁcation criteria or SLICC 2012 classiﬁcation
criteria, respectively (table 4). Additional treatment fol-
lowing drug cessation such as steroids (IV or oral) or
topical treatment (steroids and tacrolimus) was reported
in 27 patients in the TNFi cohort (50%) and 1 patient
in the nbDMARD cohort (20%).
Approximately two-thirds of cases in each cohort had
VLE limited to the skin (table 4). Most common sys-
temic manifestations included digital ischaemia,
neurological involvement and respiratory involvement
(table 4). Two patients on TNFi were reported to
develop renal manifestations, one with renal vasculitis
(no biopsy), the second with renal involvement, along
with pneumonitis, new thrombus in aorta on CT angio-
gram and cANCA-positive status. Associated thrombo-
embolic events were reported in four patients (4.9%).
Systemic involvement was reported in 30/81 (37%) VLE
patients on TNFi. The patient who developed cANCA/
PR3-positive vasculitis died following the development of
haemorrhagic alveolitis (with leukocytoclastic vasculitis
on lung biopsy), new sinusitis and bilateral episcleritis
Figure 1 Nelson-Aalen plots
comparing nbDMARD and TNFi
cohorts for each outcome. (A)
Lupus-like events; (B)
Vasculitis-like events. Cumulative
hazard estimates are
demonstrated using Nelson-Aalen
plots for each drug evaluated in
the register. Infliximab appears to
have the highest risk in both
analyses, followed by etanercept
and adalimumab. nbDMARD,
non-biological disease-modifying
antirheumatic drug.
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Table 3 Univariate analysis of individual covariates of immune-mediated adverse event risk and risk of TNFi in association
with event
HR (95% CI) for
covariate
HR (95% CI) for
anti-TNF agent
Lupus-like events
Unadjusted 3.88 (1.54 to 9.23)
Age (per year) 0.98 (0.97 to 1.01) 3.79 (1.51 to 9.53)
Gender (male referent) 2.74 (1.25 to 6.00)* 3.83 (1.53 to 9.59)
Ethnicity (non-white referent) 2.90 (1.24 to 6.75)* 3.36 (1.34 to 8.43)
Rheumatoid factor-positive 1.08 (0.75 to 1.55) 3.91 (1.56 to 9.80)
Smoking (current smoking referent) 0.96 (0.49 to 1.67) 3.95 (1.57 to 9.88)
Disease duration 1.01 (0.99 to 1.04) 3.89 (1.55 to 9.77)
Baseline DAS28 1.58 (1.25 to 1.98)* 2.38 (0.90 to 6.29)
Baseline HAQ score 1.69 (1.11 to 2.56)* 2.73 (1.07 to 6.97)
Comorbidities (nil referent)
1 comorbidity 1.11 (0.65 to 1.91) 3.95 (1.58 to 9.90)
2 comorbidities 0.77 (0.34 to 1.75)
≥3 comorbidities 1.17 (0.41 to 3.38)
Methotrexate use† 0.91 (0.54 to 1.51) 3.92 (1.57 to 9.83)
Baseline methotrexate use 1.03 (0.62 to 1.72) 3.95 (1.58 to 9.88)
Sulfasalazine use† 0.30 (0.12 to 0.75)* 3.38 (1.34 to 8.51)
Baseline sulfasalazine use 0.36 (0.16 to 0.84)* 3.53 (1.41 to 8.87)
Leflunomide use† 0.73 (0.29 to 1.82) 3.92 (1.57 to 9.83)
Baseline leflunomide use 0.83 (0.33 to 2.01) 3.93 (1.56 to 9.84)
HCQ use† 1.30 (0.70 to 2.45) 4.10 (1.63 to 10.31)
Baseline HCQ use 1.57 (0.86 to 2.89) 4.02 (1.61 to 10.08)
Minocycline use† 11.20 (1.55 to 80.81)* 3.88 (1.55 to 9.72)
Baseline minocycline use 14.31 (1.98 to 103.18)* 3.88 (1.55 to 9.72)
On steroid at baseline 0.83 (0.49 to 1.36) 4.23 (1.68 to 10.62)
Vasculitis-like event
Unadjusted 2.12 (1.20 to 3.74)
Age 1.01 (0.98 to 1.03) 2.27 (1.28 to 4.03)
Gender (male referent) 0.67 (0.46 to 1.0) 2.15 (1.22 to 3.80)
Ethnicity (non-white referent) 0.51 (0.12 to 2.08) 2.17 (1.18 to 4.00)
Rheumatoid factor-positive 1.82 (1.18 to 2.78)* 2.04 (1.16 to 3.61)
Current smoking 1.30 (0.86 to 1.98) 2.14 (1.21 to 3.79)
Disease duration 1.03 (1.01 to 1.04)* 2.16 (1.20 to 3.90)
DAS score 1.42 (1.20 to 1.68)* 1.44 (0.77 to 2.69)
HAQ score 1.65 (1.19 to 2.28)* 1.78 (0.93 to 3.42)
Comorbidities (nil referent)
1 comorbidity 1.46 (0.98 to 2.19) 2.11 (1.19 to 3.72)
2 comorbidities 0.69 (0.35 to 1.38)
≥3 comorbidities 1.16 (0.48 to 2.61)
Methotrexate use† 0.68 (0.47 to 0.98)* 2.07 (1.17 to 3.67)
Baseline methotrexate use 0.79 (0.54 to 1.14) 2.07 (1.17 to 3.66)
Sulfasalazine use† 0.46 (0.29 to 0.82)* 1.84 (1.03 to 3.24)
Baseline sulfasalazine use 0.56 (0.33 to 0.97)* 1.96 (1.10 to 3.47)
Leflunomide use† 0.75 (0.38 to 1.48) 2.10 (1.19 to 3.72)
Baseline leflunomide use 0.61 (0.27 to 1.38) 2.08 (1.18 to 3.68)
HCQ use† 0.81 (0.46 to 1.41) 2.11 (1.19 to 3.74)
Baseline HCQ use 0.91 (0.51 to 1.62) 2.11 (1.19 to 3.72)
Combination nbDMARDs (≥2, including methotrexate) 0.66 (0.43 to 1.00) 2.05 (1.16 to 3.63)
On steroid at baseline 1.20 (0.82 to 1.75) 2.07 (1.16 to 3.67)
The association between candidate confounders and the outcome (first lupus/vasculitis-like event), irrespective of the treatment group. The
final column reports the effect of each baseline covariate on the estimated treatment effect.
*p<0.05.
†Use of nbDMARD versus not use during the study period (assumes the risk returns to baseline as soon as the patient is off the drug).
Anti-TNF, tumour necrosis factor-α inhibitor; DAS28, 28 joint count Disease Activity Score; HAQ, Health Assessment Questionnaire;
nbDMARDs, non-biological disease-modifying antirheumatic drugs.
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while on adalimumab. However, systemic treatment with
IV methylprednisolone+/−cyclophosphamide was
required in the minority of patients treated with TNFi
(n=10, 12.3%).
Outcome following event
Of the 39 patients with LLE, outcomes included com-
plete resolution (72%), partial resolution (+/−revision
of diagnosis from RA to mixed connective tissue
disease/SLE with on-going treatment) (15%), 1 death
(2%) and unknown (11%). In patients who switched to
a different biologic following LLE, there was a trend for
some patients to have recurrent events on a second/
third TNFi compared to switching to rituximab (see
online supplementary ﬁgure S2). However, quantitative
comparisons could not be made due to low numbers of
subsequent events. There were three deaths reported in
relation to VLEs.
DISCUSSION
This study is the ﬁrst prospective observational study to
speciﬁcally assess the risk of lupus and vasculitis events
in patients with RA treated with TNFi. Although
unadjusted estimates conferred an increased risk of LLE
and VLE individually in TNFi-treated patients, following
adjustment this no longer remained signiﬁcant.
These data must be interpreted carefully with some
clinically important points to take from these analyses.
First, the absolute risk of LLE and VLE remains very
small with an incidence rate of 10 and 15 per 10 000
pyrs of follow-up in the TNFi-treated cohort, respectively.
Second, the majority of events was limited to cutaneous
manifestations in both subsets, with resolution of symp-
toms (+/−treatment) in most of the LLE episodes.
Third, there were inherent limitations common to obser-
vational studies. There are clear differences between the
nbDMARD and TNFi-treated cohorts, the latter as
expected and as per the national guidelines, have more
severe disease at baseline, which may in turn be a risk
factor for the events examined. Indeed, we found
factors that reﬂect baseline disease severity were asso-
ciated with higher rates of LLE and VLE. We addressed
this issue of confounding by indication, by adjustment
using a propensity score. The adjusted analysis of LLE
and VLE separately did not demonstrate a signiﬁcant
risk attributable to the TNFi itself. It was not possible to
distinguish if these cases would have occurred due to RA
or TNFi treatment; however, the association of high-
disease activity with VLE/LLE would suggest that uncon-
trolled disease may be responsible for triggering such
events. While propensity scores address confounders
present at baseline, they do not take into account time-
varying confounders such as steroid use, disease activity
and changing nbDMARD use or dose over the course of
the study. Statistical techniques, such as marginal struc-
tural modelling, have been used to address time-varying
confounders in RA previously;22 however, not used in
this case as the required variables to generate weights
were not measured at regular time points. Finally, while
the comparator cohort of nbDMARD active disease
patients is one of the strengths of the study, it is import-
ant to note the comparator includes exposure to drugs
also associated with drug-induced lupus and vasculitis
events. Therefore, while there may be no signiﬁcant dif-
ferences in adjusted risk when the two groups are com-
pared, this may be due to comparison with a group of
patients already at a higher risk of LLE/VLE. Such expo-
sures may therefore introduce bias towards the null
hypothesis. We accounted for this by performing sensi-
tivity analyses, which excluded patients on putative drugs
in both cohorts, which did not signiﬁcantly change in
the adjusted estimates.
To date, there have been few studies that were able to
robustly assess drug-speciﬁc risk of these immune-
mediated AEs. Such studies have not been adequately
powered to deﬁnitively answer this question. In our
study, inﬂiximab appeared to carry the highest incidence
rates of LLE and VLE, followed by etanercept and adali-
mumab. The highest risk observed with inﬂiximab in
the unadjusted analysis may be due to the fact that
patients started on the drug were from a historical
cohort and experienced more severe disease at the
outset. However, after adjustment for confounders, 95%
CIs overlapped. Prior studies have faced a number of
limitations, including imprecise reported events from
spontaneous pharmacovigilance, lack of an accurate
denominator of TNFi-exposed patients and absence of
an adequate comparator to assess rare outcomes such as
immune-mediated AEs.2 8 9 13 A French pharmacovigi-
lance study recently attempted to examine drug-speciﬁc
risk of LLEs from spontaneous reports, across all indica-
tions (including inﬂammatory bowel disease), and used
a positive and negative control as comparators (known
lupus-inducer isoniazid and paracetamol, respectively).23
In contrast to our study, inﬂiximab and adalimumab
Figure 2 Spline model demonstrating time-varying risk of
lupus and vasculitis events in the TNFi cohort. Hazard for
lupus- and vasculitis-like events over time in TNFi cohort,
using a flexible parametric spline model. TNFi, tumour
necrosis factor-α inhibitor.
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were found to be associated with higher rates, with eta-
nercept conferring a comparatively lower risk, although
95% CIs also overlapped with all three drugs. Similar to
our study, of the 39 cases, few fulﬁlled SLE classiﬁcation
criteria. Other descriptive studies reported higher rates
with inﬂiximab and etanercept for LLE2 and VLE.9
LLE and VLE appeared to have a time-varying risk in
the TNFi-treated cohort. The observation of greater
risk of certain outcomes early in the disease course has
been described previously with serious infections,
including septic arthritis.24–26 For LLE/VLE, there may
be a number of possible hypotheses to explain this risk
pattern. First, it may be that TNFi patients have more
severe disease at baseline (the latter associated with the
outcome), which then improves with therapy therefore
reﬂecting a reduction in risk. Second, it may indicate a
depletion of susceptible individual’s effect from the
TNFi cohort, whereby patients who remain on the
drugs are those who can tolerate them while those who
are susceptible to the event select themselves out of the
population at risk. Third, it may be that patients who
are prone to developing LLE and VLE have a genetic
predisposition to SLE/vasculitis, through shared
genetic pathways common to RA and SLE for
instance,27 and following a TNFi exposure ‘trigger’
develops the event early in the course of treatment,
unblinding a condition that may have developed
regardless. Fourth, it is possible that such events are
associated with immunogenicity of the biologic, leading
to secondary inefﬁcacy (loss of response)28–30 and even-
tual switching to another biologic, which would mean
such events occur early in the disease course. Finally, it
may reﬂect a true reduction in risk of these events over
time.
Table 4 Descriptive characteristics of lupus and vasculitis-like events
Characteristics
nbDMARD
cohort
n (%)
TNFi cohort
n (%) Characteristics
nbDMARD
cohort
n (%)
TNFi cohort
n (%)
Lupus-like events Vasculitis-like events
Limited to cutaneous
manifestations only
Cutaneous involvement (all)
Malar rash
Discoid rash
Photosensitive rash
SCLE rash
Other†
Missing description‡
Alopecia
Mouth ulcers
Constitutional symptoms
Serositis (pericardial/pulmonary
involvement)
New arthralgia§
Haematological involvement
Neurological involvement
Renal involvement
New ANA-positive
Anti-dsDNA-positive
Low complement (C3/C4)
Antiphospholipid
antibodies-positive
ACR SLE criteria met
SLICC SLE criteria met
3 (60)
4 (80)
2 (50)
1 (25)
–
1 (25)
–
–
–
1 (20)
1 (20)
–
2 (40)
–
–
1 (20)
4 (80)
2 (40)
–
–
1 (20)
2 (40)
30 (55.5)
48 (89)
6 (12.5)
8 (16.7)
8 (16.7)
2 (4.1)
17 (35.4)
7 (14.6)
7 (13.0)
5 (9.2)
6 (11.1)
4 (7.4)
10 (18.5)
5 (9.3)
2 (3.7)
4 (7.4)
30 (55.6)
12 (22.2)
5 (9.3)
1 (1.9)
9 (16.7)
11 (20.0)
Limited to cutaneous manifestations
only (included urticarial, bullous,
purpuric and ulcerating lesions)
*Systemic involvement
Digital ischaemia
Nailfold vasculitis
Neurological involvement (small
vessel vasculitis confirmed on sural
biopsy; mononeuritis multiplex)
Respiratory involvement (including
cavitating lung lesions; pneumonitis
and pulmonary emboli)
ENT
Renal involvement
Ocular involvement (including
temporal branch retinal vein
occlusion of vasculitis type and
episcleritis)
Associated thromboembolism
ANCA-positive
Requiring IV methylprednisolone
+/−cyclophosphamide
9 (64.3)
5 (35.7)
2 (14.3)
–
1 (7.1)
–
–
–
1 (7.1)
–
–
1 (7.1)
51 (63.0)
30 (37.0)
11 (13.6)
14 (17.3)
6 (7.4)
6 (7.4)
3 (3.7)
2 (2.5)
2 (2.5)
4 (4.9)
5 (6.2)
10 (12.3)
*Systemic involvement in VLE cases refers to extra-cutaneous involvement outlined below. In the VLE cases, ANCA status was not checked
or reported in the majority of cases, with five patients with known positive status during the event (four patients pANCA-positive/MPO −ve
and one patient cANCA-positive, PR3-positive).
†Other rashes included maculopapular, bullous, chilblain lupus rashes.
‡Patients with missing details regarding their cutaneous involvement were reported as ‘cutaneous lupus’ by the treating physician in
conjunction with other lupus manifestations. Other positive serology detected in TNFi-treated patients with LLE included anti-Ro/La
antibodies, antiribonucleoprotein (RNP) antibodies, perinuclear antineutrophil cytoplasmic antibodies (pANCA) positivity, antihistone
antibodies in one patient each.
§No cases were classified as LLE solely on the basis of being ANA-positive and new arthralgia. All such cases developed arthralgia and
other SLE manifestations concomitantly.
ACR, American College of Rheumatology; ANA, antinuclear antibodies; dsDNA, double-stranded DNA; nbDMARDs, non-biological
disease-modifying antirheumatic drugs; ENT, ear, nose and throat;SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus
erythematosus; SLICC, Systemic Lupus International Collaborating Clinics; TNFi, tumour necrosis factor-α inhibitor.
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The strengths of this study are the well-characterised
large sample size, systematic reporting of AEs from mul-
tiple sources (patients and clinicians) to improve valid-
ity, a comparator cohort that was simultaneously
recruited and had active disease, making it as similar as
possible to the TNFi arm. Missing baseline data were low
and to minimise potential bias, multiple imputation was
used. Additionally, classiﬁcation of LLEs was attempted,
as well as quantifying drug-speciﬁc risk of TNFi.
Although certolizumab patients are included in the
analysis and no events were reported, inferences drawn
from this are limited due to shorter follow-up and low
numbers of recruited patients. Since we only included
patients on ﬁrst TNFi drug in the analysis, we excluded
many patients on this drug who were switchers (includ-
ing one patient who developed LLE). Patients on certoli-
zumab had clear baseline differences to the rest of the
TNFi cohort, including lower disease severity and higher
concomitant nbDMARD use, which may also contribute
to eventual lower rates. We also excluded patients with
baseline SLE and systemic vasculitis; therefore, these
results cannot be extrapolated to patients with overlap of
these conditions. ANA was not consistently measured or
reported in patients at baseline; therefore, it was not
possible to assess if the presence/emergence of ANA
affects future risk of clinical events. While certain VLEs,
such as digital ischaemia and serious thrombotic events,
were observed in our study (and previously associated
with antidrug antibody formation7), our patients did not
have serum samples collected; therefore, evaluation of
immunogenicity (or antiphospholipid antibodies where
status was absent) could not be performed.
CONCLUSIONS
The increased risk in the TNFi group of LLE and VLE
was not signiﬁcant after full adjustment of baseline cov-
ariates, suggesting no increased risk following adjust-
ment for confounding by indication. The addition of
TNFi to nbDMARD, therefore, does not alter the risk of
either event in patients with RA selected for TNFi. The
absolute risk of LLE and VLE remains low. The risk of
both events was time-varying and highest in the ﬁrst year
of treatment. Clinicians should be aware of these rare
but potentially important events in TNFi-treated
patients, especially as their presentation may not fulﬁl
usual classiﬁcation criteria at the outset.
Author affiliations
1Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and
Repair, University of Manchester, Manchester Academic Health Science
Centre, Manchester, UK
2Centre for Musculoskeletal Research, Institute of Inflammation and Repair,
University of Manchester, Manchester Academic Health Science Centre,
Manchester, UK
3National Institute of Health Research Manchester Musculoskeletal Biomedical
Research Unit, Central Manchester Foundation Trust and University of
Manchester, Manchester Academic Health Science Centre, Manchester, UK
Twitter Follow Meghna Jani @MeghnaJani
Acknowledgements The authors acknowledge the enthusiastic collaboration
of all consultant rheumatologists and their specialist nurses in the UK in
providing the data. The authors gratefully acknowledge the support of the
National Institute for Health Research, through the Comprehensive Local
Research Networks at participating centres. In addition, the authors
acknowledge support from the BSR Executive, the members of the BSR
Registers and Research Committee and the BSRBR-RA Project Team in
London for their active role in enabling the register to undertake its tasks. The
authors also acknowledge the seminal role of the BSR Clinical Affairs
Committee for establishing national biological guidelines and
recommendations for such a register. Finally, the authors acknowledge the
Arthritis Research UK Centre for Epidemiology who provided the infrastructure
support for the study.
Collaborators The web reference of the BSRBR-RA is as follows: http://
research.bmh.manchester.ac.uk/Musculoskeletal/research/CfE/
pharmacoepidemiology/bsrbr/healthprofessionals/FullAuthorshipList/. The
BSRBR Control Centre Consortium consists of the following institutions (all in
the UK): Antrim Area Hospital, Antrim (Dr Nicola Maiden), Cannock Chase
Hospital, Cannock Chase (Dr Tom Price), Christchurch Hospital, Christchurch
(Dr Neil Hopkinson), Royal Derby Hospital, Derby (Dr Sheila O’Reilly),
Dewsbury and District Hospital, Dewsbury (Dr Lesley Hordon), Freeman
Hospital, Newcastle-upon-Tyne (Dr Ian Griffiths), Gartnavel General Hospital,
Glasgow (Dr Duncan Porter), Glasgow Royal Infirmary, Glasgow (Professor
Hilary Capell), Haywood Hospital, Stoke-on-Trent (Dr Andy Hassell), Hope
Hospital, Salford (Dr Romela Benitha), King’s College Hospital, London
(Dr Ernest Choy), Kings Mill Centre, Sutton-In Ashfield (Dr David Walsh),
Leeds General Infirmary, Leeds (Professor Paul Emery), Macclesfield District
General Hospital, Macclesfield (Dr Susan Knight), Manchester Royal Infirmary,
Manchester (Professor Ian Bruce), Musgrave Park Hospital, Belfast (Dr Allister
Taggart), Norfolk and Norwich University Hospital, Norwich (Professor David
Scott), Poole General Hospital, Poole (Dr Paul Thompson), Queen Alexandra
Hospital, Portsmouth (Dr Fiona McCrae), Royal Glamorgan Hospital,
Glamorgan (Dr Rhian Goodfellow), Russells Hall Hospital, Dudley (Professor
George Kitas), Selly Oak Hospital, Selly Oak (Dr Ronald Jubb), St Helens
Hospital, St Helens (Dr Rikki Abernethy), Weston General Hospital,
Weston-super-Mare (Dr Shane Clarke/Dr Sandra Green), Withington Hospital,
Manchester (Dr Paul Sanders), Withybush General Hospital, Haverfordwest
(Dr Amanda Coulson), North Manchester General Hospital (Dr Bev Harrison),
Royal Lancaster Infirmary (Dr Marwan Bukhari) and The Royal Oldham
Hospital (Dr Peter Klimiuk).
Contributors MJ and KLH were responsible for the study concept and design.
BSRBR Control Centre Consortium carried out acquisition of data. MJ, ML and
LK-F wrote the statistical analysis. MJ, WGD and KLH drafted the manuscript.
MJ and KLH had full access to all the data in the study and take responsibility
for the integrity of the data and the accuracy of the data analysis.
Funding MJ is supported by an NIHR clinical lectureship and was a Medical
Research Council Clinical Training Fellow supported by the North West
England Medical Research Council Fellowship Scheme in Clinical
Pharmacology and Therapeutics, which is funded by the Medical Research
Council (grant number G1000417/94909), ICON, GlaxoSmithKline,
AstraZeneca and the Medical Evaluation Unit. WGD was supported by an MRC
Clinician Scientist Fellowship (G092272). This report includes independent
research supported by the National Institute for Health Research. The authors
thank the Arthritis Research UK for their support (grant number 20380). This
work was supported by the British Society for Rheumatology (BSR). The BSR
commissioned the BSR Biologics Register in rheumatoid arthritis
(BSRBR-RA) as a UK wide national project to investigate the safety of
biological agents in routine medical practice. DPS and KLH are principal
investigators on the BSRBR-RA. BSR receives restricted income from UK
pharmaceutical companies, presently Abbvie, Celltrion, Hospira, Pfizer,
Samsung, UCB and Roche, and in the past Swedish Orphan Biovitrum and
MSD. This income finances a wholly separate contract between the BSR and
the University of Manchester. The principal investigators and their team have
full academic freedom and are able to work independently of pharmaceutical
industry influence.
Disclaimer The views expressed in this publication are those of the author(s)
and not necessarily those of the NHS, the National Institute for Health
10 Jani M, et al. RMD Open 2017;3:e000314. doi:10.1136/rmdopen-2016-000314
RMD Open
group.bmj.com on April 21, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
Research or the Department of Health. All decisions concerning analyses,
interpretation and publication are made autonomously of any industrial
contribution. Members of the University of Manchester team, BSR trustees,
committee members and staff complete an annual declaration in relation to
conflicts of interest. All relevant information regarding serious AEs outlined in
the manuscript have been reported to the appropriate company as per the
contractual agreements/standard operating procedures.
Competing interests MJ has received honoraria/speaker’s fees from Pfizer,
Abbvie and UCB. HC has received honoraria, speaker’s fees or grants from
Abbvie, Pfizer, UCB, Roche and Celgene. AB has received honoraria, speaker’s
fees or grants from Abbvie, Pfizer, Eli-Lilly and Sanofi-Aventis. INB has
received honoraria, speaker’s fees or grants GSK, Roche, Pfizer, UCB and
Genzyme/Sanofi. KLH has received grants from Pfizer and speaker’s fees from
Abbvie.
Ethics approval North West Multicentre Research Ethics Committee
(reference 00/8/53).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric
anti-tumour necrosis factor alpha monoclonal antibody) versus
placebo in rheumatoid arthritis patients receiving concomitant
methotrexate: a randomised phase III trial. ATTRACT Study Group.
Lancet 1999;354:1932–9.
2. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune
diseases induced by TNF-targeted therapies: analysis of 233 cases.
Medicine (Baltimore) 2007;86:242–51.
3. Takase K, Horton SC, Ganesha A, et al. What is the utility of routine
ANA testing in predicting development of biological DMARD-induced
lupus and vasculitis in patients with rheumatoid arthritis? Data from a
single-centre cohort. Ann Rheum Dis 2014;73:1695–9.
4. Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associate
with loss of response to antitumour necrosis factor-alpha therapy in
psoriasis: a retrospective, observational study. Br J Dermatol
2010;162:780–5.
5. Hoffmann JHO, Hartmann M, Enk AH, et al. Autoantibodies in
psoriasis as predictors for loss of response and anti-infliximab
antibody induction. Br J Dermatol 2011;165:1355–8.
6. Ladizinski B, Lee KC. Infliximab-induced urticaria. J Emerg Med
2014;46:691–2.
7. Korswagen LA, Bartelds GM, Krieckaert CLM, et al. Venous and
arterial thromboembolic events in adalimumab-treated patients with
antiadalimumab antibodies: a case series and cohort study. Arthritis
Rheum 2011;63:877–83.
8. De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus
erythematosus induced by anti-tumour necrosis factor alpha therapy:
a French national survey. Arthritis Res Ther 2005;7:R545–51.
9. Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha
antagonists: a study in 39 patients in France. Joint Bone Spine
2006;73:710–13.
10. Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing
the immunogenicity of TNF inhibitors in chronic inflammatory
diseases. Rheumatology (Oxford) 2014;53:213–22.
11. National Institute for Health and Clinical Excellence. Rheumatoid
arthritis—adalimumab, etanercept and infliximab (TA130). http://
guidancenice.org.uk/TA130 (2007).
12. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire
modified to assess disability in British patients with rheumatoid
arthritis. Br J Rheumatol 1986;25:206–9.
13. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to
anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum
2008;37:381–7.
14. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus.
Rheumatology (Oxford) 2009;48:716–20.
15. Dubois’ Lupus Erythematosus and Related Syndromes 8th edition—
ISBN: 9781437718935| US Elsevier Health Bookshop. http://www.
us.elsevierhealth.com/rheumatology/
dubois-lupus-erythematosus-and-related-syndromes-expert-consult/
9781437718935/ (accessed 4 Apr 2015).
16. Hochberg MC. Updating the American College of Rheumatology
Revised criteria for the classification of systemic lupus
erythematosus. Arthritis Rheum 1997;40:1725.
17. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the
Systemic Lupus International Collaborating Clinics classification
criteria for systemic lupus erythematosus. Arthritis Rheum
2012;64:2677–86.
18. Mercer LK, Lunt M, Low ALS, et al. Risk of solid cancer in patients
exposed to anti-tumour necrosis factor therapy: results from the
British Society for Rheumatology Biologics Register for Rheumatoid
Arthritis. Ann Rheum Dis 2015;76:1087–93.
19. Goeb V, Berthelot JM, Joly P, et al. Leflunomide-induced subacute
cutaneous lupus erythematosus. Rheumatology 2005;44:823–4.
20. Mor A, Pillinger MH, Wortmann RL, et al. Drug-induced arthritic and
connective tissue disorders. Semin Arthritis Rheum 2008;38:249–64.
21. Radic ́ M, Martinovic ́ Kaliterna D, Radić J. Drug-induced vasculitis: a
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The surname of the third author of this paper was spelt incorrectly. The correct
surname is “Kearsley-Fleet”.
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